Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
RegulatoryapprovedLISRAYAPositive
AI Analysis
Summary
Roivant announced FDA approval of LISRAYA (brepocitinib) for adults with dermatomyositis, marking the first approved treatment in this indication and enabling market availability in the U.S.
Outcome Details
FDA approved LISRAYA (brepocitinib) 30 mg for treatment of adults with dermatomyositis
Importance:9/10
Sentiment:
0.95
FDA approvaldermatologyautoimmunecommercial launch
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 27, 2026 7:29 PM